MiMedx Group, Inc. (MDXG)
MDXG Stock Price Chart
Explore MiMedx Group, Inc. interactive price chart. Choose custom timeframes to analyze MDXG price movements and trends.
MDXG Company Profile
Discover essential business fundamentals and corporate details for MiMedx Group, Inc. (MDXG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Feb 2008
Employees
837.00
Website
https://www.mimedx.comCEO
Joseph H. Capper
Description
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
MDXG Financial Timeline
Browse a chronological timeline of MiMedx Group, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$0.03, while revenue estimate is $63.46m.
Earnings released on 29 Apr 2026
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $58.99m , missing expectations by -10.35%.
Earnings released on 25 Feb 2026
EPS came in at $0.14 surpassing the estimated $0.09 by +55.56%, while revenue for the quarter reached $118.10m , beating expectations by +10.60%.
Earnings released on 29 Oct 2025
EPS came in at $0.15 surpassing the estimated $0.07 by +114.29%, while revenue for the quarter reached $113.73m , beating expectations by +6.35%.
Earnings released on 30 Jul 2025
EPS came in at $0.10 surpassing the estimated $0.06 by +66.67%, while revenue for the quarter reached $98.61m , beating expectations by +5.66%.
Earnings released on 30 Apr 2025
EPS came in at $0.06 matching the estimated $0.06, while revenue for the quarter reached $88.21m , beating expectations by +2.18%.
Earnings released on 26 Feb 2025
EPS came in at $0.07 matching the estimated $0.07, while revenue for the quarter reached $92.91m , beating expectations by +3.90%.
Earnings released on 30 Oct 2024
EPS came in at $0.05 surpassing the estimated $0.04 by +13.64%, while revenue for the quarter reached $84.06m , missing expectations by -6.00%.
Earnings released on 31 Jul 2024
EPS came in at $0.08 matching the estimated $0.08, while revenue for the quarter reached $87.21m , missing expectations by -1.93%.
Earnings released on 30 Apr 2024
EPS came in at $0.07 surpassing the estimated $0.05 by +40.00%, while revenue for the quarter reached $84.71m , beating expectations by +6.74%.
Earnings released on 28 Feb 2024
EPS came in at $0.04 falling short of the estimated $0.08 by -50.00%, while revenue for the quarter reached $86.83m , beating expectations by +2.10%.
Earnings released on 30 Oct 2023
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $81.71m , missing expectations by -3.92%.
Earnings released on 1 Aug 2023
EPS came in at $0.01 surpassing the estimated $0.01 by +100.00%, while revenue for the quarter reached $81.26m , beating expectations by +8.59%.
Earnings released on 2 May 2023
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $71.68m , beating expectations by +11.73%.
Earnings released on 28 Feb 2023
EPS came in at -$0.02 matching the estimated -$0.02, while revenue for the quarter reached $74.38m , missing expectations by -0.23%.
Earnings released on 2 Nov 2022
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $67.69m , beating expectations by +1.44%.
Earnings released on 2 Aug 2022
EPS came in at -$0.11 falling short of the estimated -$0.06 by -83.33%, while revenue for the quarter reached $66.88m , beating expectations by +2.79%.
Earnings released on 3 May 2022
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $58.89m , beating expectations by +8.86%.
Earnings released on 28 Feb 2022
EPS came in at $0.01 surpassing the estimated $0.00 by +129.89%, while revenue for the quarter reached $67.41m , beating expectations by +5.84%.
Earnings released on 2 Nov 2021
EPS came in at -$0.04 surpassing the estimated -$0.08 by +50.00%, while revenue for the quarter reached $63.07m , beating expectations by +4.67%.
Earnings released on 3 Aug 2021
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $68.17m , beating expectations by +15.99%.
MDXG Stock Performance
Access detailed MDXG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
